Clinical Trials with Volanensorsen (ISIS-APOCIIIrx): Familial Chylomicronemia Syndrome and Partial Lypodystrophy

James Radke, PhD

Paula Soteropoulos, president and chief executive officer of Akcea Therapeutics, a subsidiary of Isis Pharmaceuticals focused on delivering transformative medicines for cardiometabolic lipid disorders, talks about the phase 3 clinical studies the company is conducting to bring volanesorsen (ISIS-APOCIIIRX) to market. 

To learn more about the clinical trials, go to
Printer Printing...